The Medicines Company (MDCO)
(Delayed Data from NSDQ)
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.89 USD
+0.61 (1.95%)
Updated May 3, 2019 04:00 PM ET
After-Market: $31.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?
by Zacks Equity Research
Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.
Theravance's Infection Drug Vibativ Positive in TOUR Study
by Zacks Equity Research
Theravance Biopharma, Inc. (TBPH) recently released positive interim data from the ongoing TOURstudy evaluating how Vibativ (telavancin) is used to treat patients with bacteremia or infective endocarditis (IE).
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
Bear of the Day: Medicines Co (MDCO)
by Brian Hamilton
Appeals Court opens door for generic competition to Angiomax in 2H of 2015, revenues decline.
4 Health Care Stocks to Watch Out for this Earnings Season
by Zacks Equity Research
Health care companies have been attracting a lot of attention lately.
Strong Stocks for a Weak Market
by David Bartosiak
Don't let this weak market scare you. Buy into the strength.